Patient centricity: lip service or genuine commitment? A qualitative examination of the pharmaceutical industry

IF 1.2 Q4 HEALTH POLICY & SERVICES
L. Katsanis, D. Pitta, A. Morinville
{"title":"Patient centricity: lip service or genuine commitment? A qualitative examination of the pharmaceutical industry","authors":"L. Katsanis, D. Pitta, A. Morinville","doi":"10.1108/ijphm-02-2020-0010","DOIUrl":null,"url":null,"abstract":"The purpose of this study is two-fold: first, to identify the degree of adoption of patient centricity in the pharmaceutical industry and second, to understand how the industry operationalizes this strategy. It is an important shift in the industry because of its central focus on the patient.,A content analysis was used based on publicly available documentation that includes industry publications, company and brand websites and clinical trial publications to identify the frequency of words used to describe patient centricity.,The key finding of this study is that the leading pharmaceutical firms overwhelmingly use patient support/access programs as the primary method of implementing patient centric strategies.,Future research is needed to identify what impact these strategies have on patients; and whether or not these strategies have an impact on lowering drug prices and improved clinical outcomes for patients.,Future research is needed to identify what impact these strategies have on patients; and whether or not these strategies have an impact on lowering drug prices and improved clinical outcomes for patients. Limitations include the reliance on publicly available documentation.,Pharmaceutical firms need to be aware that their publically available profile suggests a one-dimensional approach to patient centricity and this may influence the way patients, physicians and policymakers view their attitudes toward patients. This study is the first to systematically examine the activities of leading pharmaceutical firms with respect to the adoption and implementation of patient-centric strategies in a comprehensive fashion.,This study is the first to systematically examine the activities of leading pharmaceutical firms with respect to the adoption and implementation of patient-centric strategies in a comprehensive fashion.","PeriodicalId":51798,"journal":{"name":"International Journal of Pharmaceutical and Healthcare Marketing","volume":"15 1","pages":"106-133"},"PeriodicalIF":1.2000,"publicationDate":"2020-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pharmaceutical and Healthcare Marketing","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1108/ijphm-02-2020-0010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 3

Abstract

The purpose of this study is two-fold: first, to identify the degree of adoption of patient centricity in the pharmaceutical industry and second, to understand how the industry operationalizes this strategy. It is an important shift in the industry because of its central focus on the patient.,A content analysis was used based on publicly available documentation that includes industry publications, company and brand websites and clinical trial publications to identify the frequency of words used to describe patient centricity.,The key finding of this study is that the leading pharmaceutical firms overwhelmingly use patient support/access programs as the primary method of implementing patient centric strategies.,Future research is needed to identify what impact these strategies have on patients; and whether or not these strategies have an impact on lowering drug prices and improved clinical outcomes for patients.,Future research is needed to identify what impact these strategies have on patients; and whether or not these strategies have an impact on lowering drug prices and improved clinical outcomes for patients. Limitations include the reliance on publicly available documentation.,Pharmaceutical firms need to be aware that their publically available profile suggests a one-dimensional approach to patient centricity and this may influence the way patients, physicians and policymakers view their attitudes toward patients. This study is the first to systematically examine the activities of leading pharmaceutical firms with respect to the adoption and implementation of patient-centric strategies in a comprehensive fashion.,This study is the first to systematically examine the activities of leading pharmaceutical firms with respect to the adoption and implementation of patient-centric strategies in a comprehensive fashion.
以病人为中心:嘴上说说还是真心实意?对制药业的定性研究
这项研究的目的有两个:第一,确定制药行业采用以患者为中心的程度,第二,了解该行业如何实施这一战略。这是该行业的一个重要转变,因为它以患者为中心。,内容分析基于公开的文件,包括行业出版物、公司和品牌网站以及临床试验出版物,以确定用于描述以患者为中心的词语的频率。,这项研究的关键发现是,领先的制药公司绝大多数将患者支持/获取计划作为实施以患者为中心的战略的主要方法。,未来的研究需要确定这些策略对患者的影响;以及这些策略是否对降低药品价格和改善患者的临床结果有影响。,未来的研究需要确定这些策略对患者的影响;以及这些策略是否对降低药品价格和改善患者的临床结果有影响。局限性包括对公开文件的依赖。,制药公司需要意识到,他们公开的个人资料表明了以患者为中心的一维方法,这可能会影响患者、医生和决策者看待他们对患者态度的方式。这项研究首次系统地考察了领先制药公司在采用和实施以患者为中心的战略方面的活动。,这项研究首次系统地考察了领先制药公司在采用和实施以患者为中心的战略方面的活动。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.10
自引率
8.30%
发文量
21
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信